The clinicopathological features and survival of Castleman disease: A multicenter Turkish study

Simple item page
dc.contributor.authorYildiz J.
dc.contributor.authorBagci M.
dc.contributor.authorSayin S.
dc.contributor.authorKaya A.
dc.contributor.authorYilmaz F.
dc.contributor.authorEkinci O.
dc.contributor.authorDal M.S.
dc.contributor.authorBasturk A.
dc.contributor.authorAydogdu I.
dc.contributor.authorAlbayrak M.
dc.contributor.authorDogan A.
dc.contributor.authorErkurt M.A.
dc.contributor.authorKorkmaz S.
dc.contributor.authorUlas T.
dc.contributor.authorEser B.
dc.contributor.authorAltuntas F.
dc.date.accessioned2024-07-22T08:05:07Z
dc.date.available2024-07-22T08:05:07Z
dc.date.issued2022
dc.description.abstractObjective: In this study, we aimed to investigate the clinicopathological features and survival of CD, which is quite rare and has many unknowns. Patients and Methods: This study was conducted by retrospectively evaluating patients diagnosed with CD in six different centers in Turkey. Results: The median age of 33 patients included in the study was 49 and 51.5% (n = 17) of these patients were women. 18 (54.5%) patients were in the hyaline vascular subtype and most of the patients were UCD (n = 20, 60.6%). The most common involvement region was head and neck (n = 19, 57.5%). The UCD group was younger than the MCD group (p=0.027). Visceral lymph node involvement was higher in MCD than in UCD (p=0.001). Similarly, it was observed that there was more hepatomegaly (p=0.035) and splenomegaly (p=0.013) in the MCD group. During the median 19.5 months follow-up period, there were no patients who died. Conclusions: It was observed that UCD and MCD are different clinical entities. Promising survival times can be achieved with surgical and systemic treatments in both subtypes of this extremely rare disease. However, this result should be supported by well-designed prospective comprehensive studies. © 2022 Verduci Editore s.r.l. All rights reserved.
dc.identifier.DOI-ID10.26355/eurrev_202202_28103
dc.identifier.issn11283602
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12992
dc.language.isoEnglish
dc.publisherVerduci Editore s.r.l
dc.subjectCastleman Disease
dc.subjectFemale
dc.subjectHumans
dc.subjectLymph Nodes
dc.subjectMale
dc.subjectProspective Studies
dc.subjectRetrospective Studies
dc.subjectTurkey
dc.subjectcyclophosphamide
dc.subjectcyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine
dc.subjectcyclophosphamide plus doxorubicin plus prednisone plus vincristine
dc.subjectcyclophosphamide plus prednisone plus rituximab plus vincristine
dc.subjectdoxorubicin
dc.subjectglucocorticoid
dc.subjectprednisone
dc.subjectrituximab
dc.subjectunclassified drug
dc.subjectvincristine
dc.subjectadult
dc.subjectaged
dc.subjectangiofollicular lymph node hyperplasia
dc.subjectArticle
dc.subjectclinical article
dc.subjectclinical feature
dc.subjectcontrolled study
dc.subjectdeath
dc.subjectfemale
dc.subjectfollow up
dc.subjecthead and neck disease
dc.subjecthepatomegaly
dc.subjecthistopathology
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectlymph node dissection
dc.subjectlymphadenopathy
dc.subjectmale
dc.subjectmulticenter study (topic)
dc.subjectpatient assessment
dc.subjectrare disease
dc.subjectretrospective study
dc.subjectsplenomegaly
dc.subjectsurvival
dc.subjectsurvival time
dc.subjectsystemic therapy
dc.subjectTurkey (republic)
dc.subjectvascular disease
dc.subjectvery elderly
dc.subjectyoung adult
dc.subjectangiofollicular lymph node hyperplasia
dc.subjectclinical trial
dc.subjectepidemiology
dc.subjectlymph node
dc.subjectmulticenter study
dc.subjectpathology
dc.subjectprospective study
dc.subjectturkey (bird)
dc.titleThe clinicopathological features and survival of Castleman disease: A multicenter Turkish study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu